This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CDP 860

UCB SA

Drug Names(s): CDP 860, Anti-PDGFR Antibody

Description: CDP860 is a PEGylated antibody fragment targeting the PDGF-beta receptor.

Deal Structure: In September 2010, Bristol-Myers Squibb and ZymoGenetics signed definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash. The transaction, with an aggregate purchase price of approximately $885 million, or approximately $735 million net of cash acquired, has been unanimously approved by the boards of directors of both companies. The acquisition was completed in October 2010.

Partners: Bristol-Myers Squibb Company


CDP 860 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug